Oncotelic Therapeutics Featured in Editorial Highlighting Innovative Cancer and Rare Disease Pipeline

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a NetworkNewsWire editorial titled "Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth" (https://ibn.fm/WpGOO). The editorial highlights the company's leadership in developing RNA-based, immunotherapy, and targeted therapeutics that address critical unmet medical needs in aggressive cancers and pediatric rare diseases. This recognition comes as the biotechnology sector continues to experience significant growth driven by innovative treatment approaches.

Under the leadership of chair and CEO Dr. Vuong Trieu, Oncotelic is advancing a robust portfolio supported by more than 500 patent applications and 75 issued patents. The company leverages cutting-edge technologies including artificial intelligence, nanomedicine, and novel clinical models to transform the treatment landscape for cancer and rare diseases. This extensive intellectual property portfolio provides a strong foundation for the company's development programs and positions it competitively within the biopharmaceutical industry.

The company's strategic approach includes both internally developed drug candidates and collaborative ventures. Oncotelic currently owns 45% of GMP Bio, a joint venture that is advancing its own pipeline of drug candidates under Dr. Trieu's leadership. This complementary pipeline further strengthens Oncotelic's position in oncology and rare disease therapeutics, creating additional value through diversified development programs. The joint venture structure allows for shared resources and expertise while maintaining focus on specific therapeutic areas.

Oncotelic's focus on high-unmet-need cancers and rare pediatric indications addresses significant market opportunities where current treatment options remain limited. The company's innovative approach to drug development, particularly in RNA-based therapies and immunotherapy, represents the next frontier in precision medicine. These advancements have the potential to improve patient outcomes while reducing treatment side effects compared to traditional cancer therapies.

The recognition by NetworkNewsWire, which is part of the Dynamic Brand Portfolio at IBN, provides increased visibility for Oncotelic's development programs. NetworkNewsWire delivers content through multiple channels including wire distribution to 5,000+ outlets, enhanced press release services, and social media distribution to millions of followers. This broad reach helps bring important biomedical developments to investors, healthcare professionals, and the general public. Additional information about the company is available through its newsroom at https://ibn.fm/OTLC.

The biotechnology and pharmaceutical industries continue to evolve with increased focus on targeted therapies and personalized medicine approaches. Oncotelic's pipeline, supported by substantial intellectual property and innovative technology platforms, positions the company to contribute meaningfully to this evolution. The development of effective treatments for aggressive cancers and rare pediatric diseases represents not only significant commercial opportunity but also the potential to address substantial patient needs that have historically been underserved by conventional therapeutic approaches.